GlaxoSmithKline ( (GSK) ) has provided an update. GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with ...

London: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a ...

GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps: London, UK Saturday, January 4, 2025, 09:00 Hrs [IST] GSK plc announced ...

China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK ...

GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that ...

GSK (NYSE:GSK) has received Chinese regulatory approval for its drug Nucala, also known as mepolizumab, for the treatment of ...

On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab) as an add-on ...

(Alliance News) - GSK PLC on Friday reported that its Nucala treatment has been approved in China to treat long-term sufferers of a sinus ailment following a phase 3 study.

Jiangxi Shanxiang Pharmaceutical's first generic "Sorafenib" is about to be approved The results of Fujian's centralized procurement of medical consumables are announced, and Johnson & Johnson and ...

INR:9705. bangladesh sri lanka cricket match GlaxoSmithKline's "Mepolizumab" is approved for listing in China Has Hisun recovered? Earned 240 m ...

INR:7444. bharat rummy circle GlaxoSmithKline's "Mepolizumab" is approved for listing in China Pharmaceutical and Health Industry Weekly Report (June 1st - Ju ...

INR:7584. 2024–25 saudi pro league GlaxoSmithKline's "Mepolizumab" is approved for listing in China 10,000 yuan allowance, job subsidies, increased m ...